Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...

随着患者使用 SGLT2 抑制剂时间的延长，进展为重度主动脉瓣狭窄的风险逐渐降低：使用至少 3 个月 、 6 个月、 12个月 的，进展为重度主动脉瓣狭窄风险分别降低 46%、 52%和 72%。 研究者分析 ，其作用机制可能是多种途径共同作用的结果，有研究发现， 钙化的主动脉瓣叶上 SGLT2 受体过度表达，可以推断，通过抑制这些受体来减轻炎症和细胞内钙含量，能够降低病情进展速度。 研究者还指出 ...

A new study, authored by KBH Professor Jan Inge Henter and published in the New England Journal of Medicine, has investigated ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

衰老细胞在人体多种组织中的积累会导致病理性衰老，清除衰老细胞（senolysis）可改善与年龄相关的疾病。目前已有研究表明，热量限制可延长多种生物的寿命，且与衰老细胞的组织积累减少有关。同时也有研究报道SGLT2抑制剂可抑制衰老细胞的积累。然而，衰老 ...

慢性肾脏病（CKD）可进展为终末期肾病（ESKD），需要透析或移植，给家庭和社会带来沉重负担。CKD患者常伴有心血管疾病，死亡风险随肾功能下降而增加。因此，延缓CKD进展和减少心血管事件是管理CKD的关键措施。近年来，钠-葡萄糖协同转运蛋白2（SGL ...